[199 Pages Report] The Vaccine Contract Manufacturing Market size was estimated at USD 5.06 billion in 2023 and expected to reach USD 5.51 billion in 2024, at a CAGR 9.21% to reach USD 9.39 billion by 2030.
Vaccine contract manufacturing refers to outsourcing vaccine production processes to third-party organizations, known as contract manufacturing organizations (CMOs). These specialized companies possess the expertise, equipment, and facilities to produce vaccines at various stages, from initial development to full-scale production and packaging. Vaccine manufacturers partner with CMOs to expedite the development and manufacturing process, leverage specialized capabilities, manage costs, and ensure supply chain flexibility. The vaccine contract manufacturing market encompasses companies that provide a range of services on a contract basis for the pharmaceutical industry. This includes the production of vaccines at various stages, from early-stage development, such as preclinical trials, through to large-scale commercial production. It often involves upstream processes, such as antigen production, and downstream processes, including filling, finishing, and packaging. Vaccine contract manufacturers serve as critical partners for pharmaceutical firms, biotechnology companies, and research institutions that require additional capability or expertise in vaccine production. The vaccine contract manufacturing is growing due to increasing outbreaks of infectious diseases worldwide, growing governmental regulations and support for vaccine development, and rising vaccinations of newborns and children. However, the market faces certain challenges, such as the high cost associated with vaccines and the lack of proper storage infrastructure. On the other hand, technological advancements in mRNA vaccine technology and strategic partnerships and collaborations with governments and non-governmental organizations present potential opportunities for the vaccine contract manufacturing market.
An attenuated vaccine uses a live version of the virus or bacteria that has been weakened, which cannot cause disease in people with healthy immune systems. This type of vaccine elicits a strong immune response and often requires fewer doses for long-term immunity. DNA vaccines employ a piece of genetic material from a pathogen to elicit an immune response. They direct the body's cells to produce an antigen that is native to the pathogen, prompting a specific immune response. DNA vaccines are still a relatively new technology and offer potential advantages in speed of development and stability, making them an interesting avenue for contract manufacturing. Inactivated vaccines contain viruses or bacteria that have been killed through physical or chemical processes. These vaccines do not pose a risk of causing the disease itself and are stable, making them suitable for a broad range of environments. Inactivated vaccines generally require adjuvants to enhance the immune response and may require multiple doses. Subunit vaccines include only the essential antigens of a virus or bacteria—rather than the whole pathogen. This approach minimizes the risk of side effects and is particularly useful when the pathogen cannot be cultivated in vitro or when the whole organism is unnecessary for immunization. Toxoid vaccines contain inactivated toxic compounds produced by bacteria that cause illness rather than the bacteria itself. These vaccines train the immune system to fight off the natural toxin, offering protection if the immunized individual ever encounters the actual pathogen. They are particularly useful for bacteria, such as Clostridium tetani, the cause of tetanus, where toxin production is the main cause of disease.
Downstream processing refers to the phase of vaccine manufacturing where the bulk product is refined and purified to meet regulatory standards and quality requirements. Key steps in downstream processing include the separation of cells and virus particles, removal of contaminants, and concentration and formulation of the vaccine. The need for downstream processing arises from the necessity to ensure that vaccines are safe, pure, and effective before they can be administered to the public. Upstream processing in vaccine manufacturing includes all steps necessary for the growth and initial harvest of the vaccine-producing biological system. This generally involves the culturing of cells or microorganisms that generate the vaccine antigen. The preference for cutting-edge upstream processing technologies stems from the fundamental need for consistent, scalable, and high-yield vaccine production.
The need for vaccine contract manufacturing in the human use segment is primarily driven by the global need to protect populations against infectious diseases. This segment encompasses the production of vaccines for a vast range of conditions, from annual influenza shots to immunizations against emerging public health threats, including COVID-19. Vaccine contract manufacturing for veterinary applications addresses the need for immunizations within animal populations, including both livestock and companion animals. The segment ensures the health of animals, which is crucial for food security and the prevention of zoonotic diseases that can transfer to humans.
The Americas region, with countries such as the United States and Canada, is characterized by advanced healthcare systems and a high degree of health awareness among the population. The United States stands as a prominent country in vaccine research. It has a vibrant ecosystem for biotech patents, with the government, industry, and academia actively investing in new vaccine technologies. In South America, increasing investment in biotechnology, government incentives for pharmaceutical manufacturing, growing public health expenditure, and the presence of bio-manufacturing facilities support the adoption of vaccine contract manufacturing. Europe has a mature vaccine contract manufacturing industry, benefiting from high-quality manufacturing standards and a stringent regulatory landscape. European Union (EU) countries actively engage in research and innovation, with a strong network of biotech firms and research institutes. The Middle East, while historically reliant on imported vaccines, is gradually developing its vaccine manufacturing capabilities, with nations including the United Arab Emirates and Saudi Arabia investing in local production facilities. Africa's market is heavily influenced by global health initiatives and partnerships focused on providing access to vaccines for all economic backgrounds. Asia Pacific represents a dynamic and rapidly growing vaccine contract manufacturing market due to its large population base, increasing healthcare expenditures, and growing awareness of the need for immunizations. Nations such as India and China are at the forefront, with a substantial number of manufacturing facilities contributing to the global vaccine supply. China has made significant investments in biotech and vaccine innovation, emphasizing the importance of technological upgrades. Japanese companies are investing in next-generation vaccines, including mRNA and DNA-based vaccines, while the government supports research through initiatives.
The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
Vaxcyte, Inc. has reinforced its collaboration with Lonza Group AG, a contract development and manufacturing organization, to ensure the global launch preparedness of its line of pneumococcal conjugate vaccines (PCVs), namely VAX-24 and VAX-31, intended to protect both adult and pediatric demographics. In a significant deal, Vaxcyte will rely on Lonza's considerable manufacturing expertise to expedite the clinical progression of its vaccine candidates, beginning with VAX-24 in the US adult market. To meet the expected long-term worldwide demand, Lonza is dedicated to the establishment of a custom manufacturing suite at their state-of-the-art Ibex Dedicate Biopark in Visp, Switzerland, with the completion of its construction design and equipment installation slated for 2024. [Published On: 2023-10-16]
Oxford Acquires ABL Europe From Institut Mérieux For EUR 15 Mn
Oxford Biomedica plc, a vaccine contract development and manufacturing organization (CDMO), has purchased ABL Europe SAS from TSGH SAS, part of the Institut Mérieux Group, for a total consideration of EUR 15 million. The deal encompasses EUR 10 million of liquid assets infused into ABL Europe by Institut Mérieux before completion. The integration of ABL Europe into Oxford Biomedica's operations is expected to catapult the latter into the vanguard of global CDMOs within the cell and gene therapy field, enhancing its service offering and increasing its production capabilities, especially in process and analytical development, as well as early-stage manufacturing. [Published On: 2023-04-12]
Pfizer Inks USD 183M Contract Manufacturing Deal With Samsung Biologics
Samsung Biologics has confirmed its contract with Pfizer Inc. to manufacture COVID-19 vaccines for Moderna in a regulatory announcement, valued at 241 billion WON (USD 183 million), valid through 2029. As disclosed by the company, Samsung is directing substantial investment into the development of antibody-drug conjugates (ADCs), with manufacturing capabilities anticipated to come online within the year at their Incheon facility, fostering growth and diversification in their service offerings. [Published On: 2023-03-02]
The report delves into recent significant developments in the Vaccine Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc, Ajinomoto Bio-Pharma Services by Ajinomoto Co., Inc., Aton (Shanghai) Biotech Co., Ltd., Avid Bioservices, Inc., Catalent, Inc., Charles River Laboratories International, Inc., CSL Limited, Curia Global, Inc., Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd., Emergent BioSolutions Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, Gedeon Richter PLC, GlaxoSmithKline PLC, ICON PLC, IDT Biologika GmbH, KBI Biopharma, Inc. by JSR Corporation, Klocke Pharma-Service GmbH, Lonza Group Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Pharmaceutical Product Development by Thermo Fisher Scientific Inc., Recipharm AB, Serum Institute of India, and Vetter Pharma-Fertigung GmbH & Co. KG.
This research report categorizes the Vaccine Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Type
- Attenuated Vaccine
- DNA Vaccines
- Inactivated Vaccine
- Subunit Vaccines
- Toxoid Vaccines
- Function
- Downstream
- Analytical & QC studies
- Fill & Finish Operations
- Packaging
- Upstream
- Bacterial Expression Systems
- Baculovirus or Insect Expression Systems
- Mammalian Expression Systems
- Yeast Expression Systems
- Downstream
- Application
- Human Use
- Veterinary
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Vaccine Contract Manufacturing Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Contract Manufacturing Market?
- What are the technology trends and regulatory frameworks in the Vaccine Contract Manufacturing Market?
- What is the market share of the leading vendors in the Vaccine Contract Manufacturing Market?
- Which modes and strategic moves are suitable for entering the Vaccine Contract Manufacturing Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Vaccine Contract Manufacturing Market, by Type
- Vaccine Contract Manufacturing Market, by Function
- Vaccine Contract Manufacturing Market, by Application
- Americas Vaccine Contract Manufacturing Market
- Asia-Pacific Vaccine Contract Manufacturing Market
- Europe, Middle East & Africa Vaccine Contract Manufacturing Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 22]
- List of Tables [Total: 468]
- List of Companies Mentioned [Total: 25]
Firstly, what is vaccine contract manufacturing? It is the process of outsourcing the manufacturing of vaccines to a third-party organization. Contract manufacturers specialize in the production and development of vaccines, both for commercial and clinical purposes. The increasing demand for vaccines has led to capacity expansion by contract manufacturers, with some companies even building new facilities to raise production levels.
The reasons behind the growing demand for vaccine contract manufacturing are numerous. Foremost, vaccines are currently the primary solution being sought against COVID-19 and other infectious diseases, leading to a surge in vaccine demand. Major pharmaceutical companies have also identified the need to focus on their core competencies and outsource vaccine production to contract manufacturers. Additionally, outsourcing vaccine production helps to cut costs, allowing companies to allocate their resources to research, development, and sales.
Besides increased capacity and cost savings, engaging a vaccine contract manufacturer offers many other benefits. These contract manufacturing facilities have state-of-the-art equipment, trained personnel, and strict quality control standards that minimize production risks and improve the final product quality. Contract manufacturers are also better equipped to navigate regulatory hurdles and ensure compliance with the regulatory authorities.
Vaccine contract manufacturing has also brought about a significant technological revolution in the vaccine industry. Contract manufacturers have the resources and expertise to optimize processes, develop new formulations and delivery technologies, and improve manufacturing standards. This has led to the development of novel vaccines and improved quality control processes, enabling faster and more efficient vaccine development.
In conclusion, vaccine contract manufacturing is essential to the increasing demand for vaccines globally. Contract manufacturers handle everything from research and development to commercial-scale production, allowing pharmaceutical companies to focus on their core competencies. Outsourcing vaccine production helps companies reduce costs, improve quality control, and minimize risks. Therefore, embracing and leveraging the technological advancements brought about by vaccine contract manufacturing is essential to address the ever-growing vaccine demand.
As the world battles the COVID-19 pandemic and other infectious diseases, it is becoming evident that vaccines are integral to saving lives and achieving herd immunity. Vaccine contract manufacturing offers a solution to the increased global demand for vaccines. Through quality control, technological revolution, and optimizing production processes, this service allows for increased production, reduced costs, and better quality. The pharmaceutical industry must embrace and leverage the benefits of vaccine contract manufacturing to meet the increasing vaccine demand.
- How big is the Vaccine Contract Manufacturing Market?
- What is the Vaccine Contract Manufacturing Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?